PTPRC and neoplasm: There were an increase in the percentage of type 1 conventional dendritic cells (cDC1s: CD45+Ly6C–CD3–CD19–TCR–CD11c+MHCII+CD172loXCRhi) (P = 0.047) and a corresponding decrease in tumor-associated macrophages (TAMs) (F4/80hiMHCIIhiCD64hi) within YUMMER1.7 tumors after combination anti–PD-1/anti-MIF therapy when compared with the ctrl group (P = 0.039) (Figure 3, B and C).